Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment
| Autor: | Salvatore, Di Maria, Francesca, Picarazzi, Mattia, Mori, Annarita, Cianciusi, Anna, Carbone, Emmanuele, Crespan, Cecilia, Perini, Samantha, Sabetta, Serenella, Deplano, Federica, Poggialini, Alessio, Molinari, Rossella, Aronne, Elias, Maccioni, Giovanni, Maga, Adriano, Angelucci, Silvia, Schenone, Francesca, Musumeci, Elena, Dreassi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Organic Chemistry
Abl Chronic myeloid leukemia Fusion Proteins bcr-abl Antineoplastic Agents Biochemistry Piperazines Pyrimidines Drug Resistance Neoplasm Kinase inhibitors Leukemia Myelogenous Chronic BCR-ABL Positive 4-d]pyrimidines Benzamides Drug Discovery Pyrazolo[3 Imatinib Mesylate Humans Protein Kinase Inhibitors Molecular Biology Src |
| Popis: | The Bcr-Abl tyrosine kinase (TK) is the molecular hallmark of chronic myeloid leukemia (CML). Src is another TK kinase whose involvement in CML was widely demonstrated. Small molecules active as dual Src/Bcr-Abl inhibitors emerged as effective targeted therapies for CML and a few compounds are currently in clinical use. In this study, we applied a target-oriented approach to identify a family of pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl inhibitors as anti-leukemia agents. Considering the high homology between Src and Bcr-Abl, in-house Src inhibitors 8a-l and new analogue compounds 9a-n were screened as dual Src/Bcr-Abl inhibitors. The antiproliferative activity on K562 CML cells and the ADME profile were determined for the most promising compounds. Molecular modeling studies elucidated the binding mode of the inhibitors into the Bcr-Abl (wt) catalytic pocket. Compounds 8j and 8k showed nanomolar activities in enzymatic and cellular assays, together with favorable ADME properties, emerging as promising candidates for CML therapy. Finally, derivatives 9j and 9k, emerging as valuable inhibitors of the most aggressive Bcr-Abl mutation, T315I, constitute a good starting point in the search for compounds able to treat drug-resistant forms of CML. Overall, this study allowed us to identify more potent compounds than those previously reported by the group, marking a step forward in searching for new antileukemic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|